ConductScience.org, home

Paper34834201

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.

Salvador-Martín S and 2 others. Pharmaceutics, 2021. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Papers, record 34834201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34834201

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.
PubMed
Journal
Pharmaceutics
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.37
iCite
Revised in PubMed
2021-11-30
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Salvador-Martín SSara
2Melgarejo-Ortuño AAlejandrahttps://orcid.org/0000-0001-6273-7487
3López-Fernández LALuis Ahttps://orcid.org/0000-0003-3964-5837

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PI19/00792Instituto de Salud Carlos IIIPubMed

Source PubMed

Download CSV of grants

References128

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129027257Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Aliment Pharmacol Ther2017https://conductscience.org/library/papers/29027257PubMed
222643596Is pediatric IBD treatment different than in adults?Minerva Gastroenterol Dietol2012https://conductscience.org/library/papers/22643596PubMed
329618496Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD.Gut2019https://conductscience.org/library/papers/29618496PubMed
428272355Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment.Int J Mol Sci2017https://conductscience.org/library/papers/28272355PubMed
531126015A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.Int J Mol Sci2019https://conductscience.org/library/papers/31126015PubMed
629957083How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease.Expert Rev Gastroenterol Hepatol2018https://conductscience.org/library/papers/29957083PubMed
727636407Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review.J Clin Gastroenterol2017https://conductscience.org/library/papers/27636407PubMed
824162032Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.Gastroenterology2014https://conductscience.org/library/papers/24162032PubMed
929487490Pediatric Crohn's Disease.Clin Colon Rectal Surg2018https://conductscience.org/library/papers/29487490PubMed
1029202588Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.Expert Opin Drug Saf2018https://conductscience.org/library/papers/29202588PubMed
1132813123Infliximab in young paediatric IBD patients: it is all about the dosing.Eur J Pediatr2020https://conductscience.org/library/papers/32813123PubMed
1231777929Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.J Crohns Colitis2020https://conductscience.org/library/papers/31777929PubMed
1330211845Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.J Pediatr Gastroenterol Nutr2019https://conductscience.org/library/papers/30211845PubMed
1433026087The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update.J Crohns Colitis2021https://conductscience.org/library/papers/33026087PubMed
1525784738How effective is the use of long-term anti-TNF for paediatric IBD? Clues from real-life surveillance cohorts.Arch Dis Child2015https://conductscience.org/library/papers/25784738PubMed
1626308438Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.Inflamm Bowel Dis2015https://conductscience.org/library/papers/26308438PubMed
1731247074Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.Inflamm Bowel Dis2020https://conductscience.org/library/papers/31247074PubMed
1827609485Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.Gut Liver2017https://conductscience.org/library/papers/27609485PubMed
1932773718Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease.J Pediatr Gastroenterol Nutr2020https://conductscience.org/library/papers/32773718PubMed
2024776844Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.Pharmacogenomics J2014https://conductscience.org/library/papers/24776844PubMed

See all 128 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
38507036The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.Paediatr Drugs2024https://conductscience.org/library/papers/38507036PubMed
37808875Predicting pediatric Crohn's disease based on six mRNA-constructed risk signature using comprehensive bioinformatic approaches.Open Life Sci2023https://conductscience.org/library/papers/37808875PubMed
36675312Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort.Int J Mol Sci2023https://conductscience.org/library/papers/36675312PubMed
35908771JNK pathway-associated phosphatase illustrates low expression and negative correlations with inflammation, disease activity, and T-helper 17 cells in inflammatory bowel disease children.J Clin Lab Anal2022https://conductscience.org/library/papers/35908771PubMed

Download CSV of cited by

Genes101

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ADA100PubTator's text mininghttps://conductscience.org/library/genes/100NCBI Gene
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
ANOS13730PubTator's text mininghttps://conductscience.org/library/genes/3730NCBI Gene
ANXA3306PubTator's text mininghttps://conductscience.org/library/genes/306NCBI Gene
ATG129140PubTator's text mininghttps://conductscience.org/library/genes/9140NCBI Gene
ATG16L155054PubTator's text mininghttps://conductscience.org/library/genes/55054NCBI Gene
ATG59474PubTator's text mininghttps://conductscience.org/library/genes/9474NCBI Gene
ATP9A10079PubTator's text mininghttps://conductscience.org/library/genes/10079NCBI Gene
ATXN16310PubTator's text mininghttps://conductscience.org/library/genes/6310NCBI Gene
BRWD154014PubTator's text mininghttps://conductscience.org/library/genes/54014NCBI Gene
CACNA1E777PubTator's text mininghttps://conductscience.org/library/genes/777NCBI Gene
CCL76354PubTator's text mininghttps://conductscience.org/library/genes/6354NCBI Gene
CCR2729230PubTator's text mininghttps://conductscience.org/library/genes/729230NCBI Gene
CD14929PubTator's text mininghttps://conductscience.org/library/genes/929NCBI Gene
CDKAL154901PubTator's text mininghttps://conductscience.org/library/genes/54901NCBI Gene
CNBD1168975PubTator's text mininghttps://conductscience.org/library/genes/168975NCBI Gene
CNTN11272PubTator's text mininghttps://conductscience.org/library/genes/1272NCBI Gene
COL22A1169044PubTator's text mininghttps://conductscience.org/library/genes/169044NCBI Gene
COX6B2125965PubTator's text mininghttps://conductscience.org/library/genes/125965NCBI Gene
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene

See all 101 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34834201

GET https://conductscience.org/api/papers/v1/34834201/references?page=2